Conclusions: We suggest that the phenotypic and functional T-cell signature elicited by chemoimmunotherapy is a fine-tuned balance between quality of the Ag/TCR complex, co-stimulatory signals such as ICOS, inhibitory checkpoints and AKT activation, associated with anti-tumor T cells that can protect patients from tumor recurrence. The gene discussed is ICOS; the disease is neoplasm.